

Technology Advisory Committee Interests Register

Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion [ID6197]

Publication Date: 11 September 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Luke Nicholson	Clinical Expert	Direct – financial Indirect	Mr Nicholson has received: <ul style="list-style-type: none"> • speaker fees and support to attend conferences from Roche. • speaker fees from Bayer. • advisory board fees and speaker fees from AbbVie. Mr Nicholson’s nominating organisation, the Royal College of Ophthalmologists, has received grants from Roche and Bayer.	23/02/2024	It was agreed that Mr Nicholson's declaration would not prevent him from providing expert advice to the committee.
Professor Sobha Sivaprasad	Clinical Expert	Direct – financial Direct – non-financial	Professor Sivaprasad has: <ul style="list-style-type: none"> • acted as an advisor, consultant and presenter at commercial meetings for Roche. • attended advisory boards and/or received financial support from AbbVie, Bayer, Biogen and Roche. Professor Sivaprasad is a Trustee of the Macular Society.	04/03/2024	It was agreed that Professor Sivaprasad 's declaration would not prevent her from providing expert advice to the committee.